贤丰控股(002141) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥274,449,534.28, a decrease of 12.26% compared to ¥312,798,252.98 in the same period last year[2] - Net profit attributable to shareholders was ¥17,608,180.89, representing a significant increase of 275.20% from ¥4,693,041.82 in the previous year[2] - Basic and diluted earnings per share increased by 278.05% to ¥0.0155 from ¥0.0041 in the same period last year[2] - Net profit for Q1 2022 reached CNY 15,563,776.00, significantly up from CNY 1,752,108.95 in Q1 2021, marking an increase of 786.5%[20] - Basic earnings per share for Q1 2022 were CNY 0.0155, compared to CNY 0.0041 in Q1 2021, representing an increase of 278.0%[21] Cash Flow - The net cash flow from operating activities decreased by 53.82% to ¥7,385,550.42 from ¥15,993,341.53 year-on-year[2] - Total cash inflow from operating activities is ¥317,568,441.61, down from ¥354,535,163.78, reflecting a decline of 10.4%[22] - Cash outflow from operating activities totaled ¥310,182,891.19, compared to ¥338,541,822.25 in the previous period, indicating a decrease of 8.4%[24] - The net cash flow from investment activities increased significantly to ¥35,046,952.79 from ¥11,265,541.72, representing a growth of 211.5%[24] - The net cash flow from financing activities turned negative at -¥16,645,350.99, compared to a positive ¥95,869,066.04 in the previous period[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,344,120,842.74, down 3.64% from ¥1,394,959,827.53 at the end of the previous year[2] - Total liabilities decreased to CNY 480,216,122.18 from CNY 545,385,253.71, reflecting a reduction of 11.9%[17] - The company's equity attributable to shareholders increased by 2.04% to ¥820,011,693.94 from ¥803,637,142.31 at the end of the previous year[2] - The company's equity attributable to shareholders increased to CNY 820,011,693.94 from CNY 803,637,142.31, showing a growth of 2.3%[17] Expenses - The company reported a significant increase in sales expenses by 97.31% to ¥7,488,013.89, mainly due to the consolidation of Shiji Biological[8] - Research and development expenses rose by 62.54% to ¥8,837,442.94, reflecting increased investment in innovation[8] - Research and development expenses for Q1 2022 were CNY 8,837,442.94, up from CNY 5,437,133.59 in the previous year, indicating a rise of 62.5%[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 45,250[10] - Guangdong Xianfeng Holdings Co., Ltd. holds 26.03% of shares, totaling 295,358,647 shares, with 292,200,000 shares pledged and 295,358,647 shares frozen[10] - Xianfeng Holdings Group Co., Ltd. owns 14.03% of shares, amounting to 159,152,000 shares, with 114,000,000 shares frozen[10] Other Information - Non-recurring gains and losses totaled ¥29,180,871.47, primarily due to the disposal of assets by Huizhou New Energy[5] - The company has no plans to reclassify any non-recurring gains and losses as regular gains and losses[6] - The company has received a civil ruling from the Shenzhen Intermediate People's Court regarding a contract dispute, leading to the lifting of property preservation measures on its assets[12] - The company is in the process of handling the lifting of property preservation measures for its land and buildings located in Zhuhai[12] - Other comprehensive income after tax for Q1 2022 was CNY -1,233,629.26, compared to CNY 2,024,816.80 in Q1 2021[21]